<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01828359</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ALOS-401</org_study_id>
    <nct_id>NCT01828359</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.</brief_title>
  <official_title>An Eight-week, Randomized, Double-blind Multicenter Study to Compare the Efficacy and Safety of Amosartan® Tab 5/100mg Versus Cozaar® Plus Pro Tab in Patients With Essential Hypertension Uncontrolled With Losartan 100mg Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the blood pressure lowering effects of an
      amlodipine/losartan combination treatment and losartan/Hydrochlorothiazide combination
      treatment in patients with essential hypertension uncontrolled with losartan 100mg
      monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Quality assurance plan was implemented by site monitoring, including data validation and
           registry procedures and Source data verification to assess the accuracy, completeness by
           comparing the data to external data sources (medical records and paper case report
           forms).

        -  Data dictionary contains the registry, including the source of the variable, coding
           information (MedDRA ver12.0), and normal ranges.

        -  Statistical analysis were performed using SAS® Version 9.2, SAS institute, Cary, NC, USA
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MSDBP</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Mean Seated Systolic Blood Pressure (MSSBP)</measure>
    <time_frame>Baseline, Week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure responder rate</measure>
    <time_frame>Baseline, Week 4 and 8</time_frame>
    <description>Rate of patients who achieved target blood pressure (MSSBP &lt; 140 mmHg and MSDBP &lt; 90 mmHg), or MSSBP decrease &gt; 20 mmHg from baseline or MSDBP decrease &gt; 10 mmHg from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Amosartan® tab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 5mg /Losartan 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cozaar® plus pro tab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan 100mg/ HCTZ 12.5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amosartan® tab</intervention_name>
    <description>comparison of different combination of anti-hypertension drug</description>
    <arm_group_label>Amosartan® tab</arm_group_label>
    <other_name>Amlodipine 5mg /Losartan 100mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cozaar® plus pro tab</intervention_name>
    <description>comparison of different combination of anti-hypertension drug</description>
    <arm_group_label>Cozaar® plus pro tab</arm_group_label>
    <other_name>Losartan 100mg/ HCTZ 12.5mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 aged or over

          -  Patients with blood pressure measured at Visit 1; 90mmHg≤MSDBP mmHg if on
             anti-hypertensive drugs, 95mmHg≤MSDBP mmHg if not on anti-hypertensive drugs

          -  Patients with blood pressure measured at Visit 2 were 90mmHg≤MSDBP mmHg (non-responder
             to Losartan 100mg for 4-week treatment)

        Exclusion Criteria:

          -  Patients with too high Blood pressure

             •≥ sitSBP 20mmHg or ≥ sitDBP 10mmHg of variation in three measurements from the
             reference arm selected at Screening

          -  History of hypersensitivity to CCB ,Angiotensin II receptor blockers or Sulfonamide.

          -  Secondary hypertension or suspected to be
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taehoon Ahn, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2013</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

